Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Isatuximab With Carfilzomib and Pomalidomide in Relapsed or Refractory Multiple Myeloma
NCT04850599Phase 2Active, not recruiting
- Sponsor
- OHSU Knight Cancer Institute
- Start
- Jun 2022
- Primary completion
- Oct 2027
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of isatuximab in multiple myeloma (MM), sponsored by OHSU Knight Cancer Institute. Started Jun 2022; status: active, not recruiting.
02
Drugs
isatuximab
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT04850599.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04850599.